Affinity Asset Advisors, LLC Aeglea Bio Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

  • $579 Million
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$0.11 - $0.46 $539,000 - $2.25 Million
4,900,000 New
4,900,000 $2.21 Million

Others Institutions Holding AGLE

# of Institutions
1
Shares Held
241K
Call Options Held
0
Put Options Held
0
View Full List

About Aeglea BioTherapeutics, Inc.

AGLE Quotes by TradingView
  • Ticker AGLE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,172,500
  • Market Cap $1.69B
  • Description
  • Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...
More about AGLE
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email